Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals, Inc. (ARMP) EBIAT (2016 - 2018)

Armata Pharmaceuticals' EBIAT history spans 6 years, with the latest figure at -$7.6 million for Q4 2018.

  • For Q4 2018, EBIAT fell 224.4% year-over-year to -$7.6 million; the TTM value through Dec 2018 reached -$16.7 million, down 30.1%, while the annual FY2024 figure was -$18.9 million, 72.6% up from the prior year.
  • EBIAT for Q4 2018 was -$7.6 million at Armata Pharmaceuticals, down from -$2.8 million in the prior quarter.
  • Across five years, EBIAT topped out at $21.2 million in Q3 2014 and bottomed at -$20.6 million in Q4 2016.
  • The 5-year median for EBIAT is -$2.9 million (2016), against an average of -$1.7 million.
  • The largest YoY upside for EBIAT was 208.27% in 2014 against a maximum downside of 587.36% in 2014.
  • A 5-year view of EBIAT shows it stood at -$664000.0 in 2014, then surged by 919.13% to $5.4 million in 2015, then plummeted by 477.88% to -$20.6 million in 2016, then skyrocketed by 88.56% to -$2.4 million in 2017, then plummeted by 224.4% to -$7.6 million in 2018.
  • Per Business Quant, the three most recent readings for ARMP's EBIAT are -$7.6 million (Q4 2018), -$2.8 million (Q3 2018), and -$3.2 million (Q2 2018).